Andreas T.
- Country
- Germany
- Department
- Department of Medicine II
Research Overview
- N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
- A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA)
Data & Insights
Has run more than one trial at 4 of 125 partner sites.
Specializations
Liver Cancer Expertise
This investigator specializes in treating various stages of hepatocellular carcinoma (HCC), with particular focus on advanced and intermediate-stage disease manifestations.
- Advanced unresectable HCC management
- Intermediate-stage HCC treatment approaches
- Portal vein thrombosis complications
Their research encompasses Child-Pugh classified patients across different performance status levels.
Immunotherapy Applications
The investigator works extensively with novel immunotherapeutic approaches in liver cancer treatment, including combination therapies with immune checkpoint inhibitors.
- Dual immunotherapy combinations
- Targeted antibody treatments
- Immunotherapy resistance mechanisms
Their work includes innovative approaches to overcome treatment resistance in HCC patients.
Treatment Innovation
The investigator explores cutting-edge therapeutic strategies, including microbiota-based interventions and comparative treatment approaches.
- Fecal microbiota transfer applications
- Transarterial chemoembolization studies
- Combined therapeutic modalities
Their research includes assessment of novel treatment combinations and alternative therapeutic pathways.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.